Apyx Medical Corporation (APYX)
Apyx Medical Corporation is an energy technology company focused on developing and marketing medical devices for the cosmetic and surgical markets. Their key product, Renuvion, utilizes helium plasma technology for tissue coagulation and ablation.
Company Overview
Apyx Medical Corporation pioneers helium plasma technology with its Renuvion system, offering innovative solutions for tissue coagulation and ablation in the cosmetic and surgical markets, targeting a growing demand for minimally invasive procedures and improved patient outcomes.
Investment Thesis
Apyx Medical Corporation presents a compelling investment opportunity due to its innovative Renuvion technology and its potential to disrupt the cosmetic and surgical markets. The company's focus on helium plasma energy offers a unique solution for tissue coagulation and ablation, driving demand from physicians seeking minimally invasive procedures with improved patient outcomes. With a gross margin of 62.6%, Apyx demonstrates strong pricing power and efficient operations. Upcoming expansion into new geographic markets and further development of its product pipeline are key growth catalysts. While the company currently has a negative P/E ratio of -10.87 and a negative profit margin of -30.4%, strategic initiatives to improve profitability and achieve economies of scale could drive significant shareholder value. Investors should monitor the company's ability to increase market penetration and achieve profitability in the coming years.
Key Highlights
- Gross Margin of 62.6% indicates strong pricing power and efficient cost management in the production of medical devices.
- Operates in two segments: Advanced Energy and Original Equipment Manufacturing (OEM), diversifying revenue streams and market reach.
- Renuvion branded products cater to the cosmetic surgery market, a high-growth area driven by increasing demand for aesthetic procedures.
- J-Plasma branded products serve the hospital surgical market, providing access to a broader patient base and established medical infrastructure.
- Market Cap of $0.16B suggests potential for significant growth as the company expands its market share and achieves profitability.
Competitors
Strengths
- Proprietary Renuvion technology
- Strong gross margins
- Growing cosmetic surgery market
- Established brand recognition
Weaknesses
- Negative P/E ratio
- Negative profit margin
- Limited product diversification
- Dependence on Renuvion sales
Catalysts
- Upcoming: Expansion into new geographic markets, targeting increased sales in Asia-Pacific and Europe by 2027.
- Ongoing: Continued adoption of Renuvion technology by plastic surgeons and cosmetic physicians.
- Upcoming: New product launches and enhancements to the Renuvion system, expected in late 2026.
- Ongoing: Strategic partnerships with leading hospitals and medical device distributors to expand market reach.
Risks
- Potential: Competition from larger medical device companies with greater resources.
- Potential: Regulatory changes and approvals impacting the sale and use of Renuvion.
- Ongoing: Product liability claims and lawsuits related to the use of Apyx's medical devices.
- Potential: Economic downturn affecting demand for cosmetic surgery procedures.
- Ongoing: Dependence on a limited number of key customers and suppliers.
Growth Opportunities
- Geographic Expansion: Apyx has the opportunity to expand its sales and marketing efforts into new geographic markets, particularly in Asia-Pacific and Europe, where demand for cosmetic surgery and minimally invasive procedures is growing rapidly. This expansion could involve establishing direct sales teams, partnering with local distributors, or acquiring complementary businesses. Successful execution of this strategy could significantly increase Apyx's revenue and market share within the next 3-5 years.
- Product Pipeline Development: Apyx can invest in research and development to expand its product pipeline and introduce new applications for its helium plasma technology. This could include developing new handpieces, generators, or software enhancements that improve the performance, versatility, and ease of use of the Renuvion system. A robust product pipeline will help Apyx maintain its competitive advantage and attract new customers.
- Strategic Partnerships: Apyx can form strategic partnerships with leading plastic surgeons, hospitals, and medical device distributors to increase awareness and adoption of its products. These partnerships could involve co-marketing agreements, clinical trials, or joint product development initiatives. Collaborating with key opinion leaders and established healthcare providers will enhance Apyx's credibility and market reach.
- Increased Focus on OEM Segment: Apyx can leverage its expertise in energy technology to expand its OEM business, providing generators and accessories to other medical device companies. This could involve developing customized solutions for specific surgical applications or licensing its technology to larger players in the industry. Expanding the OEM segment will diversify Apyx's revenue streams and reduce its reliance on direct sales of Renuvion.
- Expansion into New Surgical Specialties: Apyx can explore opportunities to expand the use of its Renuvion system into new surgical specialties beyond cosmetic surgery, such as general surgery, orthopedic surgery, and gynecological surgery. This would require conducting clinical trials to demonstrate the safety and efficacy of Renuvion in these new applications. Successful expansion into new specialties could significantly increase Apyx's addressable market and revenue potential.
Opportunities
- Geographic expansion
- Product pipeline development
- Strategic partnerships
- Expansion into new surgical specialties
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Economic downturn
- Product liability claims
Competitive Advantages
- Proprietary Helium Plasma Technology: Apyx's Renuvion system utilizes a unique and patented technology that provides a competitive advantage in tissue coagulation and ablation.
- Established Brand Recognition: The Renuvion brand has gained recognition and acceptance among plastic surgeons and cosmetic physicians.
- Strong Gross Margins: Apyx's high gross margins indicate strong pricing power and efficient cost management.
- Growing Installed Base: The company has a growing installed base of generators, which generates recurring revenue from the sale of disposable hand pieces.
About
Apyx Medical Corporation, formerly known as Bovie Medical Corporation, was founded in 1982 and is headquartered in Clearwater, Florida. The company rebranded in January 2019 to reflect its focus on advanced energy technology. Apyx operates in the medical device industry, specifically targeting the cosmetic and surgical markets. Its core technology revolves around the use of helium plasma energy for various medical applications. The company's primary product is the Renuvion system, which utilizes a Helium Plasma Generator to deliver radiofrequency (RF) energy and helium to cut, coagulate, and ablate soft tissue during surgical procedures. Renuvion is particularly popular in the cosmetic surgery market, where it enables plastic surgeons, facial plastic surgeons, and cosmetic physicians to provide controlled heat to tissue for desired aesthetic results. Apyx also offers J-Plasma branded products for the hospital surgical market. In addition to the generators, Apyx develops, manufactures, and sells disposable handpieces, OEM generators, and accessories, providing a comprehensive suite of products for its customers. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM).
What They Do
- Develops and manufactures medical devices using energy technology.
- Offers Helium Plasma Generators for cutting, coagulating, and ablating soft tissue.
- Provides Renuvion branded products for cosmetic surgery.
- Offers J-Plasma branded products for hospital surgical markets.
- Sells disposable hand pieces and OEM generators.
- Provides accessories for their medical devices.
Business Model
- Sells Helium Plasma Generators and related accessories to hospitals and cosmetic surgery centers.
- Generates revenue from the sale of disposable hand pieces used with the generators.
- Offers OEM generators and accessories to other medical device companies.
- Provides service and maintenance for its installed base of generators.
Industry Context
Apyx Medical Corporation operates within the medical device industry, a sector characterized by continuous innovation and increasing demand for minimally invasive surgical procedures. The cosmetic surgery market, in particular, is experiencing significant growth, driven by rising disposable incomes and an aging population seeking aesthetic enhancements. The competitive landscape includes companies such as Atos Medical (ATOS), Lucida Medical (LUCD), Inspire Medical Systems (NSPR), Pulmatrix (PDEX), and Quipt Home Medical (QIPT), each offering various solutions within the broader medical device space. Apyx differentiates itself through its proprietary helium plasma technology, which offers unique benefits in tissue coagulation and ablation.
Key Customers
- Plastic surgeons and cosmetic physicians.
- Hospitals and surgical centers.
- OEM partners in the medical device industry.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $13M | -$2M | $0.00 |
| Q2 2025 | $11M | -$4M | $0.00 |
| Q1 2025 | $9M | -$4M | $0.00 |
| Q4 2024 | $14M | -$5M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Apyx Medical Corporation (APYX) stock price: $3.84 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the growth potential.
- •Community sentiment has seen a positive shift, with discussions highlighting the innovative nature of Apyx's technology in the medical field.
- •Analysts are noting an increased interest from institutional investors, which often precedes significant market movements and can bolster stock stability.
- •Recent product developments and partnerships have generated excitement, positioning Apyx as a strong player in the surgical products market.
Why Bear
- •Concerns about regulatory approvals have surfaced, creating uncertainty around the timeline for new product launches and market entry.
- •Social media sentiment has shown some skepticism, with discussions around potential competition that could impact market share.
- •The overall market volatility in the healthcare sector has raised red flags, leading some investors to adopt a cautious approach.
- •Recent earnings reports have not met expectations, which has led to bearish sentiment among traders regarding the company's short-term performance.
Latest News
-
Earnings Scheduled For November 6, 2025
benzinga · Nov 6, 2025
-
Earnings Scheduled For August 7, 2025
benzinga · Aug 7, 2025
-
Earnings Scheduled For May 8, 2025
benzinga · May 8, 2025
-
Earnings Scheduled For March 13, 2025
benzinga · Mar 13, 2025
Technical Analysis
Rationale
AI-generated technical analysis for APYX including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Apyx Medical Corporation (APYX) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for APYX.
Make a Prediction
Set your price target for Apyx Medical Corporation (APYX), choose a timeframe, and track your prediction accuracy.
Current price: $3.84
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for APYX.
Price Targets
Wall Street price target analysis for APYX.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 2/100
Revenue declined -8.1% YoY, signaling shrinking demand or market headwinds.
-
Gross Margin 10/100
Gross margin of 62.6% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 3/100
Net insider selling of +$0.02M may indicate reduced confidence or routine diversification by executives.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates APYX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Apyx Medical Corporation do?
Apyx Medical Corporation is an energy technology company that develops, manufactures, and sells medical devices for the cosmetic and surgical markets. Its primary product is the Renuvion system, which utilizes helium plasma technology to deliver radiofrequency energy for tissue coagulation and ablation. The company targets plastic surgeons, cosmetic physicians, and hospitals, offering a range of generators, handpieces, and accessories. Apyx operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM), providing solutions for both direct sales and partnerships with other medical device companies.
Is APYX stock a good buy?
APYX stock presents a mixed investment profile. The company's innovative Renuvion technology and strong gross margins of 62.6% are positive indicators. However, the negative P/E ratio of -10.87 and negative profit margin of -30.4% raise concerns about profitability. Growth catalysts include geographic expansion and new product launches. Investors should carefully consider the company's financial performance, growth potential, and competitive landscape before making an investment decision. Monitoring the company's progress towards profitability and market share gains is crucial.
What are the main risks for APYX?
Apyx Medical Corporation faces several risks, including competition from larger medical device companies with greater resources and established market presence. Regulatory changes and approvals could impact the sale and use of Renuvion. Product liability claims and lawsuits related to the use of Apyx's medical devices pose a significant threat. An economic downturn could reduce demand for cosmetic surgery procedures, affecting the company's revenue. Additionally, Apyx's dependence on a limited number of key customers and suppliers could create vulnerabilities in its supply chain and sales channels.
Is APYX a good stock to buy?
Whether APYX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the APYX MoonshotScore?
The MoonshotScore for APYX is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is APYX data updated?
APYX stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to APYX is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for APYX?
Growth catalysts for Apyx Medical Corporation (APYX) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Apyx Medical Corporation's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are APYX's main competitors?
Apyx Medical Corporation (APYX) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether APYX has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about APYX?
Wall Street analyst coverage for APYX includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is APYX's market cap?
Market capitalization (market cap) for APYX is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows APYX's current market cap alongside enterprise value and other valuation metrics.
How has APYX stock performed recently?
APYX's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing APYX's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in APYX?
Key risk categories for APYX include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures APYX's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling APYX?
Insider trading activity for APYX tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is APYX a good stock for beginners?
Apyx Medical Corporation (APYX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is APYX for first-time investors?
Every stock carries risk, including Apyx Medical Corporation (APYX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like APYX.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data may be subject to change.
- Investment decisions should be based on thorough research and consultation with a financial advisor.